The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

Christian Marth, ENGOT Chair, AGO-Austria, Andreas du Bois, ENGOT Vice-Chair; AGO Germany, Christian Schauer (AGO-Austria), Andreas du Bois (AGO-Germany), Antonio Casado (EORTC GCG), Ignace Vergote (BGOG), José Maria del Campo (GEICO), Athina Goudopoulou (HECOG), Eric Pujoade-Lauraine (GINECO), Ilan Bruchim (ISGO), Nicoletta Colombo (ManGO), Sandro Pignata (MITO), Jonathan Ledermann (NCRI/MCR), Radoslav Chekerov (NOGGO), Mansoor Raza Mirza (NSGO), Anneke Westermann (DGOG), Ros Glasspool (SGTCG), Cagatay Taskiran (TSGO), Mathias Fehr (SAKK), and David Cibula (CEEGOG)

Key Words: Gynecologic oncologic trials, Partnership

Received February 26, 2015, and in revised form March 3, 2015. Accepted for publication March 4, 2015.

The European Network for Gynaecological Oncological Trial Groups (ENGOT) is a research network of the European Society of Gynaecological Oncology and was founded in Berlin in October 2007.

The European Network for Gynaecological Oncological Trial Groups is, according to its Mission Statement, a platform that guarantees that European spirit and culture are incorporated into medical progress in gynecologic oncology and that all European patients and European countries can participate in an active way in clinical research and progress.

The ultimate goals are to bring the best treatment to patients with gynecologic cancer through the best science and to enable every patient in every European country to have access to a clinical trial.

In keeping with this statement, ENGOT accepts only European groups as full members. However, in the interest of accomplishing our mission, close collaboration with other groups or networks can be helpful. To improve such collaboration, it has been decided to create a Privileged Partnership as follows:

1. A Privileged Partner (PP) must be a Gynaecological Oncological Trial Group outside Europe that is interested in long-term collaboration with ENGOT and participation in ENGOT trials.
2. Formal application for PP status must be approved by two-thirds of ENGOT member groups.
3. PP status is granted for a period of 5 years and may be renewed on reapplication.
4. A PP has the right to propose a trial to ENGOT. Such a PP-proposed study can be designated as an ENGOT trial if the requirements of the ENGOT roadmap are met: (http://www.esgo.org/Documents/ENGOT_Roadmap_for_trials_version01.06.12.pdf). Final approval of each trial proposal will be made by ENGOT.
5. According to ENGOT rules, the global leading group of a trial must be determined by ENGOT. After that decision, the leading group appoints the principal investigator. In exceptional cases, a PP can be assigned as leading group.
6. All ENGOT groups and PPs are advised to inform possible industry partners about this stipulation up front.
7. In concordance with the ENGOT roadmap, most of the participating sites must come from ENGOT groups.
8. Selection of groups for participation in an ENGOT trial is made by ENGOT. The PP agrees to conduct all studies in countries represented by ENGOT in cooperation with ENGOT. Vice versa, if centers are needed in a country represented by the PP, ENGOT will ask the PP first.
9. ENGOT guidelines for publication must be met (see ENGOT Roadmap) and the same criteria are applicable for ENGOT trials in collaboration with PPs.

Christian Marth, ENGOT Chair
Andreas du Bois, ENGOT Vice-Chair

Representatives of ENGOT groups: Christian Schauer (AGO-Austria), Andreas du Bois (AGO-Germany), Antonio Casado (EORTC GCG), Ignace Vergote (BGOG), José María del Campo (GEICO), Athina Goudopoulou (HECOG), Eric Pujade-Lauraine (GINECO), Ilan Bruchim (ISGO), Nicoletta Colombo (ManGO), Sandro Pignata (MITO), Jonathan Ledermann (NCRI/MCR), Radoslav Chekerov (NOGGO), Mansoor Raza Mirza (NSGO), Anneke Westermann (DGOG), Ros Glasspool (SGTCG), Cagatay Taskiran (TSGO), Mathias Ferr (SAKK), David Cibula (CEEGOG)

Approved by ENGOT Assembly on 20th February 2015, Frankfurt